 |
 Video: What is a Stock Split?
|
|
|
| Purple Biotech is a clinical-stage company developing therapies by overcoming tumor immune evasion and drug resistance. Co.'s segments are: Oncology, which includes CM24, a humanized monoclonal antibody that blocks Carcinoembryonic Antigen Related Cell Adhesion Molecule 1, and NT219, a small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 and Signal Transducer and Activator of Transcription, two signal transduction pathways involved in the development of cancer drug resistance mechanisms; and Pain and Hypertension, which includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension. According to our Purple Biotech stock split history records, Purple Biotech has had 0 splits. | |
|
Purple Biotech (PPBT) has 0 splits in our Purple Biotech stock split history database.
Looking at the Purple Biotech stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Purple Biotech shares, starting with a $10,000 purchase of PPBT, presented on a split-history-adjusted basis factoring in the complete Purple Biotech stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/23/2015 |
|
| End date: |
05/02/2024 |
|
| Start price/share: |
$2.99 |
|
| End price/share: |
$0.54 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-81.91% |
|
| Average Annual Total Return: |
-18.33% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,809.13 |
|
| Years: |
8.44 |
|
|
|
|
|
